Cairn Biosciences is developing "new generation" treatments that deal with major challenges in the treatment of serious diseases. Cairn's "Drug Discovery" philosophy responds to the profound unmet need for new tools to decipher the complexity of diseases and enable the evolutionary discovery of revolutionary therapies.
Their proprietary approach encompasses cutting-edge advances in microfluidics, high-throughput screening using synthetic biology and iPS cell-based modeling. This allows them to monitor multiple dynamic features of biology previously inaccessible in living cells. They are poised to accelerate the discovery of a set of drugs for many areas, with an initial focus on cancer.